Ajanta Pharma · NSE: AJANTPHARM · BSE: 532331
Q2 FY20 results · Jul–Sep 2019
Ajanta Pharma reported revenue from operations of ₹642.76 crore (up 18.1% from Q2 FY19) and net profit of ₹116.36 crore (down 7.2% from Q2 FY19) for Q2 FY20 (Jul–Sep 2019), on a consolidated basis.
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 642.76 | 544.11 | +18.1% | 611.94 | +5.0% |
| Other income | 13.22 | 15.24 | −13.3% | 7.64 | +73.0% |
| Total income | 655.98 | 559.35 | +17.3% | 619.58 | +5.9% |
| Profit before tax | 161.56 | 163.84 | −1.4% | 151.45 | +6.7% |
| Net profit for the period | 116.36 | 125.39 | −7.2% | 114.63 | +1.5% |
| EPS, basic (₹) | 13.34 | 14.25 | −6.4% | 13.14 | +1.5% |
| Net margin (%) | 18.1 | 23.0 | 18.7 |
| Item | Q2 FY20 | Q2 FY19 | YoY | Q1 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 559.45 | 465.29 | +20.2% | 545.74 | +2.5% |
| Other income | 39.31 | 16.93 | +132.2% | 39.62 | −0.8% |
| Total income | 598.76 | 482.22 | +24.2% | 585.36 | +2.3% |
| Profit before tax | 160.83 | 141.98 | +13.3% | 156.45 | +2.8% |
| Net profit for the period | 120.70 | 104.10 | +15.9% | 123.60 | −2.3% |
| EPS, basic (₹) | 13.83 | 11.83 | +16.9% | 14.17 | −2.4% |
| Net margin (%) | 21.6 | 22.4 | 22.6 |
Consolidated
- Filed with BSE
- 06 Nov 2019, 12:13 IST
- Board meeting
- 05 Nov 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Nov 2019, 12:13 IST
- Board meeting
- 05 Nov 2019
- Period
- 01 Jul 2019 to 30 Sep 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE